Phase I clinical trials for development of neurotherapeutics task order #001 - performance area a - administrative and overall clinical operations support
Ended Awarded Last action
- Contract number
- HHSN27100001
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $433,977
Award facts
- Opportunity
-
- NIHNINDS1501 Solicitation number
- Phase I Clinical Trials for Development of Neurotherapeutics Award Notice · Posted Jun 18, 2015
- Contract value 100% obligated
- $433,977.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Cape Fear, NC 28401, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $54,821 | |
| Exercise an Option | $53,713 | |
| Exercise an Option | $52,649 | |
| Exercise an Option | $51,605 | |
| Exercise an Option | $50,594 | |
| Exercise an Option | $49,614 | |
| Exercise an Option | $48,656 | |
| Other Administrative Action | $0 | |
| Original award | $72,325 |
About this award
This contract award to PPD Development LP by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is for Phase I clinical trials in the development of neurotherapeutics. The $433,977 firm-fixed-price delivery order is part of a larger indefinite delivery/indefinite quantity (ID/IQ) contract for this program area. The contract supports administrative and overall clinical operations, with a period of performance through June 30, 2026. As a global contract research organization, PPD Development LP has extensive experience supporting medical research and public health initiatives for federal agencies. This award does not have a set-aside designation.
Quick answers
Who was awarded contract HHSN27100001?
HHSN27100001 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on July 1, 2016.
How much is contract HHSN27100001 worth?
The government has obligated $433,977 on HHSN27100001.
Which agency awarded contract HHSN27100001?
National Institute on Drug Abuse (National Institutes of Health) awarded HHSN27100001, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract HHSN27100001 an order under another contract?
Yes. HHSN27100001 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract HHSN27100001 competed?
The extent of competition for HHSN27100001 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award